New immune checkpoint targets such as lymphocyte activation gene-3, T-cell immunoglobulin mucin-3, T cell immunoglobulin and ITIM domain, V-domain immunoglobulin suppressor of T cell activation, B7 Homolog 3, B and T lymphocyte attenuator play an important role in tumor treatment. Blocking them can delay tumor growth, enhance the anti-tumor effect of immune cells, and improve the survival rate of the host. Although these new immune checkpoints are in the early stages of research, with the continuous development of science and technology, they will play an increasingly important role in tumor immunotherapy.